A

Acrivon Therapeutics
D

ACRV

7.77000
USD
-0.56
(-6.72%)
مغلق
حجم التداول
978
الربح لكل سهم
0
العائد الربحي
0
P/E
-3
حجم السوق
241,582,871
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARMK
    -0.850
    (-2.48%)
    33.420 USD
    DELL
    -5.310
    (-4.67%)
    108.350 USD
    E
    EIGR
    0
    (0%)
    0.000000 USD
    N
    NEXI
    0
    (0%)
    0.000000 USD
    O
    OPEN
    -0.20500
    (-8.80%)
    2.12500 USD
الأخبار
المقالات

العنوان: Acrivon Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.